On August 13, 2026 BioCytics, Inc., and LIDE Biotech reported the formation of a strategic alliance to develop advanced screening platforms and companion diagnostics for immune-based cancer cell therapies. This collaboration combines BioCytics’ specialized cell manufacturing capabilities with LIDE’s unique, patient-derived xenograft technologies (PDX, miniPDX, and IO-based PDX models) to streamline the development of immuno-oncology (IO) treatments.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The initial project based on the companies’ recently-executed Memorandum of Understanding will involve the creation of murine PDX models using human biospecimens from ethically consented patients on an institutional review board (IRB)-approved BioCytics tumor and immune cells collection study (View Source) that opened in 2007 and is still ongoing. These tumor models can then be used to observe a number of critical responses, such as drug resistance or induced cell death, for cells being treated in in vivo validation studies. Further model studies will involve DNA and RNA sequencing for additional response research such as human anti-tumor immune cell function.
BioCytics’ COO, Dr. Brent Dixon, says that "working with LIDE Biotech enables real breakthroughs in personalized medicine for cancer patients. We are excited about exploring our developments for autologous adaptive immune cell therapy (AAICT) within this unique model. We expect to learn more about the molecular pathways and signatures based upon the applied analytical methodologies."
This sentiment is echoed by Dr. Danyi Wen, LIDE’s Founder and CEO, who states that "LIDE is excited for its first-ever partnership with an American-based company to further deliver on our goals to support translational research for new drug R&D as well as personalized oncology. We are looking forward to working with BioCytics and leveraging its expertise to make LIDE technologies available outside of China. BioCytics’ patient-first vision is inspiring and truly aligns with LIDE’s mission to empower more scientists, accelerate more breakthroughs, and help move promising treatments one step closer to patients in need."
(Press release, BioCytics, AUG 13, 2026, View Source [SID1234670098])